Mary E. Enama

6.5k citations

30 papers · 2.3k indexed · h-index 21

Impact in

Virology top 1%
- HIV Research and Treatment
Infectious Diseases top 1%
- Viral Infections and Vectors
- Viral Infections and Outbreaks Research
- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology

Papers in

Virology 12
- HIV Research and Treatment 11
Epidemiology 24
- Influenza Virus Research Studies 9
- Hepatitis B Virus Studies 8
- Herpesvirus Infections and Treatments 6
- Respiratory viral infections research 4

Co-authors: Barney S. Graham Robert T. Bailer Richard A. Koup Gary J. Nabel John R. Mascola Mario Roederer Charla Andrews Ingelise J. Gordon
Journals: PLoS ONE (9 papers)The Journal of Infectious Diseases (5 papers)Vaccine (4 papers)Contemporary Clinical Trials (2 papers)Clinical and Vaccine Immunology (2 papers)
Partner nations: United States Netherlands

In The Last Decade

Mary E. Enama

30 papers receiving 2.2k citations

Peers

Countries citing papers authored by Mary E. Enama

Since Specialization

Citations

This map shows the geographic impact of Mary E. Enama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary E. Enama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary E. Enama more than expected).

Fields of papers citing papers by Mary E. Enama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary E. Enama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary E. Enama. The network helps show where Mary E. Enama may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mary E. Enama, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mary E. Enama Line = papers co-authored together Mary E. Enama links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial PLoS ONE ·Cristina Carter, Katherine V. Houser, Galina V. Yamshchikov, Abbie R. Bellamy, Jeanine May, Mary E. Enama, Uzma Sarwar, Brenda Larkin, Robert T. Bailer, Richard A. Koup, Grace Chen, Shital M. Patel, Patricia Winokur, Robert B. Belshe, Cornelia L. Dekker, Barney S. Graham, Julie E. Ledgerwood, (unknown)	2019	16
2	DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial PLoS ONE ·Katherine V. Houser, Galina V. Yamshchikov, Abbie R. Bellamy, Jeanine May, Mary E. Enama, Uzma Sarwar, Brenda Larkin, Robert T. Bailer, Richard A. Koup, Myeisha Paskel, Kanta Subbarao, Edwin L. Anderson, David I. Bernstein, Danny Zomerhuis, Harry Keyserling, Paul Spearman, Peter F. Wright, Barney S. Graham, Julie E. Ledgerwood, (unknown)	2018	23
3	An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial npj Vaccines ·Adam DeZure, Emily E. Coates, Zonghui Hu, Galina V. Yamshchikov, Kathryn L. Zephir, Mary E. Enama, Sarah H. Plummer, Ingelise J. Gordon, Florence Kaltovich, Έλενα Παπαγεωργίου, Adrian B. McDermott, Michelle C. Crank, Richard A. Koup, Richard Schwartz, Robert T. Bailer, Xiangjie Sun, John R. Mascola, Terrence M. Tumpey, Barney S. Graham, Julie E. Ledgerwood	2017	20
4	Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012) PLoS ONE ·Michelle C. Crank, Eleanor Wilson, Laura Novik, Mary E. Enama, Cynthia S. Hendel, Wenjuan Gu, Martha Nason, Robert T. Bailer, Gary J. Nabel, Adrian B. McDermott, John R. Mascola, Richard A. Koup, Julie E. Ledgerwood, Barney S. Graham, (unknown)	2016	10
5	Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost Contemporary Clinical Trials ·Julie E. Ledgerwood, Zonghui Hu, Pamela Costner, Galina V. Yamshchikov, Mary E. Enama, Sarah H. Plummer, Cynthia S. Hendel, LaSonji A. Holman, Brenda Larkin, Ingelise J. Gordon, Robert T. Bailer, Donald M. Poretz, Uzma Sarwar, 梅昌新, Richard A. Koup, John R. Mascola, Barney S. Graham	2015	11
6	Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults PLoS ONE ·Michelle C. Crank, Ingelise J. Gordon, Galina V. Yamshchikov, Sandra Sitar, Zonghui Hu, Mary E. Enama, LaSonji A. Holman, Robert T. Bailer, Melissa B. Pearce, Richard A. Koup, John R. Mascola, Gary J. Nabel, Terrence M. Tumpey, Richard Schwartz, Barney S. Graham, Julie E. Ledgerwood, (unknown)	2015	20
7	DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial PLoS ONE ·Julie E. Ledgerwood, Abbie R. Bellamy, Robert B. Belshe, David I. Bernstein, Srilatha Edupuganti, Shital M. Patel, W.A. McKinley, Sundaram Ram, Richard Schwartz, Richard A. Koup, Robert T. Bailer, Galina V. Yamshchikov, Mary E. Enama, Uzma Sarwar, Brenda Larkin, Barney S. Graham, (unknown)	2015	16
8	Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial PLoS ONE ·Uzma Sarwar, Laura Novik, Mary E. Enama, Е. Г. Свиридов, Richard A. Koup, Martha Nason, Robert T. Bailer, Adrian B. McDermott, Mario Roederer, John R. Mascola, Julie E. Ledgerwood, Barney S. Graham, (unknown)	2014	5
9	Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011) PLoS ONE ·Mary E. Enama, Julie E. Ledgerwood, Laura Novik, Martha Nason, Ingelise J. Gordon, LaSonji A. Holman, Robert T. Bailer, Mario Roederer, Richard A. Koup, John R. Mascola, Gary J. Nabel, Barney S. Graham, (unknown)	2014	22
10	Randomization to standard and concise informed consent forms: Development of evidence-based consent practices Contemporary Clinical Trials ·Mary E. Enama, Zonghui Hu, Ingelise J. Gordon, Pamela Costner, Julie E. Ledgerwood, Christine Grady	2012	31
11	Influenza Virus H5 DNA Vaccination Is Immunogenic by Intramuscular and Intradermal Routes in Humans Clinical and Vaccine Immunology ·Julie E. Ledgerwood, John Thebarge, Ingelise J. Gordon, Galina V. Yamshchikov, Mary E. Enama, Sarah H. Plummer, Robert T. Bailer, Melissa B. Pearce, Terrence M. Tumpey, Richard A. Koup, John R. Mascola, Gary J. Nabel, Barney S. Graham	2012	43
12	Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses PLoS ONE ·Richard A. Koup, Mario Roederer, Laurie Lamoreaux, Jennifer Fischer, Laura Novik, Martha Nason, Brenda Larkin, Mary E. Enama, Julie E. Ledgerwood, Robert T. Bailer, John R. Mascola, Gary J. Nabel, Barney S. Graham, (unknown)	2010	102
13	A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults Vaccine ·Julie E. Ledgerwood, Pamela Costner, Niraj M. Desai, LaSonji A. Holman, Mary E. Enama, Galina V. Yamshchikov, Sabue Mulangu, Zongyi Hu, Charla Andrews, A. Rohmann, Richard A. Koup, Mario Roederer, Robert T. Bailer, John R. Mascola, Maria Grazia Pau, Nancy J. Sullivan, Jaap Goudsmit, Gary J. Nabel, Barney S. Graham	2010	141
14	A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial Vaccine ·Julie E. Martin, Mark K. Louder, L. Marcinowski, Ingelise J. Gordon, Mary E. Enama, Brenda Larkin, Charla Andrews, Leatrice Vogel, Richard A. Koup, Mario Roederer, Robert T. Bailer, Phillip L. Gomez, Martha Nason, John R. Mascola, Gary J. Nabel, Barney S. Graham	2008	197
15	A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial The Journal of Infectious Diseases ·Julie E. Martin, Theodore C. Pierson, Ilka Peter, Faye Messner, Ingelise J. Gordon, Mary E. Enama, Charla Andrews, Qing Xu, Brent S. Davis, Martha Nason, Michael P. Fay, Richard A. Koup, Mario Roederer, Robert T. Bailer, Phillip L. Gomez, John R. Mascola, Gwong‐Jen J. Chang, Gary J. Nabel, Barney S. Graham	2007	131
16	Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine Vaccine ·Andrew Catanzaro, Mario Roederer, Richard A. Koup, Robert T. Bailer, Mary E. Enama, Martha Nason, Julie E. Martin, Faye Messner, Charla Andrews, Phillip L. Gomez, John R. Mascola, Gary J. Nabel, Barney S. Graham	2007	96
17	Safety and Immunogenicity of a Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1-Seronegative Subjects JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jorge A. Tavel, Julie E. Martin, Крохалёв Александр Александрович, Mary E. Enama, Luna Alvarado Añón, Phillip L. Gomez, Charla Andrews, Richard A. Koup, Robert T. Bailer, Judy Stein, Mario Roederer, Gary J. Nabel, Barney S. Graham	2007	44
18	Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 DNA Candidate Vaccine The Journal of Infectious Diseases ·Barney S. Graham, Richard A. Koup, Mario Roederer, Robert T. Bailer, Mary E. Enama, Zoe Moodie, Julie E. Martin, 隆之小野, Bimal K. Chakrabarti, Laurie Lamoreaux, Charla Andrews, Phillip L. Gomez, John R. Mascola, Gary J. Nabel	2006	151
19	VRC 004: Safety and Immunogenicity of a Multiclade HIV-1 DNA Vaccine in Healthy Uninfected Adults (VRC-HIVDNA009-00-VP) Journal of Allergy and Clinical Immunology ·Verma Nivedita, Mary E. Enama, Richard A. Koup, Robert T. Bailer, Zoe Moodie, Mario Roederer, Gary J. Nabel, Barney S. Graham	2005	4
20	Early Bactericidal Activity of Isoniazid in Pulmonary Tuberculosis American Journal of Respiratory and Critical Care Medicine ·Richard Hafner, Dyah Puspito, David J. Wright, Nancy E. Dunlap, Merrill J. Egorin, Mary E. Enama, K Muth, Charles A. Peloquin, Han Chong, Leonid Heifets	1997	34

About Mary E. Enama

Mary E. Enama is a scholar working on Virology, Epidemiology, Immunology, Infectious Diseases and Public Health, Environmental and Occupational Health, having authored 30 papers that have together received 2.3k indexed citations. Recurring topics across this work include HIV Research and Treatment (11 papers), Immunotherapy and Immune Responses (10 papers), Influenza Virus Research Studies (9 papers), Hepatitis B Virus Studies (8 papers), Herpesvirus Infections and Treatments (6 papers), Viral Infections and Outbreaks Research (5 papers), Viral Infections and Vectors (5 papers) and Respiratory viral infections research (4 papers). The work is most often cited by research in Virology (502 citations), Infectious Diseases (1.2k citations), Immunology (702 citations), Epidemiology (811 citations) and Animal Science and Zoology (144 citations). Mary E. Enama has collaborated with scholars based in United States and Netherlands. Frequent co-authors include Barney S. Graham, Robert T. Bailer, Richard A. Koup, Gary J. Nabel, John R. Mascola, Mario Roederer, Charla Andrews, Ingelise J. Gordon, Julie E. Ledgerwood and Phillip L. Gomez. Their work appears in journals such as PLoS ONE, The Journal of Infectious Diseases, Vaccine, Contemporary Clinical Trials and Clinical and Vaccine Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact